Little interest from pharma in US FDA's drug naming pilot programme
This article was originally published in SRA
A two-year, US Food and Drug Administration pilot programme to find the best model for evaluating proposed proprietary names for medicines has drawn a poor response from the pharmaceutical industry1-3.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.